Minnesota Women’s Care Adopts Femasys Fertility Portfolio Across Four Locations
Event summary
- Minnesota Women’s Care will implement FemVue for fertility diagnostics and FemaSeed Complete for first-line fertility treatment across all four of its OB/GYN practice locations.
- Femasys Inc. announced the adoption on September 15, 2026, following its August 2026 financing round.
- Femasys plans to expand its commercial team to support broader OB/GYN adoption of its fertility portfolio.
- FemaSeed Complete combines FemaSeed with FemSperm for in-office sperm preparation, enabling practices to provide first-line fertility treatment without referrals.
The big picture
Femasys’ adoption by Minnesota Women’s Care marks a strategic milestone in its efforts to expand OB/GYN reach for its fertility portfolio. The move aligns with broader industry trends toward earlier, more accessible fertility care, potentially reducing costs and improving patient outcomes. The company’s recent financing and plans to grow its commercial team suggest a focused push to capitalize on this momentum. The scale of adoption across all four of Minnesota Women’s Care’s locations underscores confidence in Femasys’ technology and its potential to disrupt traditional fertility care pathways.
What we're watching
- Adoption Pace
- How quickly Femasys can secure additional OB/GYN practice adoptions following Minnesota Women’s Care’s implementation.
- Commercial Execution
- Whether Femasys’ expanded commercial team can effectively deepen its presence within territories and drive broader adoption.
- Market Expansion
- The pace at which Femasys can expand its fertility portfolio into key international markets beyond the U.S.